Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Eli Lilly

Options Corner: Embattled Drug Maker Novo Nordisk May Offer Speculators A Quick Profit-Scalping Opportunity

From the doldrums of the COVID-19 crisis to the early summer of 2024, few major pharmaceutical companies enjoyed as much market success as Novo Nordisk (NYSE:NVO). Much of the success was tied into the company's weight-loss drugs Wegovy and Ozempic. However, competition in the space has intensified, particularly from Eli…

Benzinga

Serena Williams reveals GLP-1 treatment helped her lose 31 pounds after giving birth

After years of struggling with postpartum weight gain despite strict training and healthy eating, the 23-time Grand Slam champion turned to a GLP-1 medication.

Euronews

Wegovy sales spike after maker of rival Mounjaro ramps up UK price

CheqUp said it had experienced a spike in interest from consumers wanting to switch or begin taking the medication.

Evening Standard

From analysis to the latest developments in health,
read the most diverse news in one place.

Sales of Wegovy weight loss jabs soar 27-fold after rival Mounjaro ramps up price in UK

CheqUp said it had experienced a spike in interest from consumers wanting to switch or begin taking the medication

The Independent UK

Ozempic Boom: Hims & Eli Lilly Lead Healthcare Bets

The race inside the weight loss industry is ramping up, leaving investors with three names to choose from in how they want to play this theme.

MarketBeat

Novo Nordisk Freezes Hiring As Wegovy Faces Copycats

Novo Nordisk A/S (NYSE:NVO) has reportedly imposed a global hiring freeze for nonessential roles, as the drugmaker faces rising competition from copycat versions of Wegovy and intensifying rivalry with Eli Lilly and Co (NYSE:LLY).

Benzinga

Viking's 42% Plunge Splits Experts—A '$129 Strong Buy' Or 'Clearly Inferior' Drug?

Viking Therapeutics Inc. (NASDAQ:VKTX) saw its stock collapse by over 42% on Tuesday after data from its Phase 2 obesity pill trial disappointed investors, sparking a fierce debate between Wall Street bulls and critical biotech experts.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Market Bloodbath: Viking Therapeutics Stock Tanks After Obesity Pill Side Effects Trigger Mass Dropouts

Viking Therapeutics shares plunged 40% after trial data for its obesity pill, VK2735, revealed high dropout rates due to side effects, raising doubts about its competitiveness against rivals Eli Lilly and Novo Nordisk.

International Business Times UK

Buy, Sell, or Hold? Insiders Pile Into These 3 Healthcare Stocks

Insiders are buying stocks like LLY, TFX, and CALC. The question is whether they are also a good buy for investors, and not all of them are.

MarketBeat

New Obesity Drugs May See Premium Pricing Undermined By Underwhelming Data

Eli Lilly and Co. (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) are expected to launch new obesity-treatment pills in the U.S. next year at prices comparable to their existing injectable drugs, signaling a break from the industry trend of charging more for new therapies.

Benzinga

Like Eli Lilly, Viking Therapeutics' Oral Weight Loss Drug Disappoints, Stock Tanks

On Tuesday, Viking Therapeutics Inc. (NASDAQ:VKTX) released the much-awaited data from its Phase 2 trial of VK2735 pill, the company’s dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.

Benzinga

2 Outstanding ‘Strong Buy’ Stocks to Grab in August

These two stocks offer a rare combination of income and growth.

Barchart

Ozempic price slashed following Donald Trump's demands - will it impact the UK cost?

Novo Nordisk said it has no plans to rise UK prices, despite pressure from Trump

Evening Standard

Weight loss drugs: how will you be affected by the Mounjaro price rise in the UK?

We’d like to hear from people who are taking Mounjaro and how they feel about the increase in cost for doses

The Guardian - UK

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Eli Lilly Considering Viking Therapeutics Acquisition? Expert Says 'They're Setting Up For Something BIG' As LLY Issues 40-Year Bond

Eli Lilly And Co.‘s (NYSE:LLY) recent, and highly unusual, issuance of a 40-year bond is fueling speculation that the pharmaceutical giant may be preparing for a major acquisition, with Viking Therapeutics Inc. (NASDAQ:VKTX) emerging as a potential target.

The Independent UK

Patients switch to Ozempic en masse as Mounjaro hikes prices

IN FULL

The Independent UK

Christopher Biggins latest celebrity to confirm he is using weight loss jabs

Actor and television personality Biggins, 76, is taking Eli Lilly jab Mounjaro

The Independent UK

Ozempic sales surge ‘up to 600%’ after Mounjaro price rises

Price hikes are 'kick in the teeth' for patients who will either have to swallow 170 per cent price increase, or switch to 'almost as good' competitor

Get all your
news in one place.

100's of premium titles.
One news app.

International Business Times UK

Ozempic Lawsuit: Patients Claim Life-Threatening Side Effects As Safety Questions Put Zepbound In The Spotlight

Over 2,000 Ozempic and Zepbound lawsuits allege life-threatening side effects as FDA updates warnings and courts weigh evidence.

The Independent UK

Voices: Pricing people out of using Mounjaro would be bad news for the NHS

COMMENT: The astronomical rise in weight-loss drug prices caused by Trump’s tariffs could have a significant – and dangerous – impact on Britain’s pharmacies and patients, writes Leyla Hannbeck, CEO of the Independent Pharmacies Association

Benzinga

Jim Cramer Says Don't Quit Market When It's Frothy: 'Is Widespread Irrationality a Reason To Sell Down in Perfectly Rational Stocks? Absolutely Not'

In the face of a frothy market, financial expert Jim Cramer encourages investors to stay the course, highlighting numerous positive stock narratives that counterbalance the market’s irrationality.

Benzinga

Novo Nordisk's Lead Fades, Eli Lilly Holds Course For Outsized Gains, Says Analyst

On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes drug Mounjaro (tirzepatide) in the United Kingdom.

International Business Times UK

Mounjaro Is About to Get More Expensive in the UK: Here Are Cheaper Alternatives Available Right Now

Mounjaro's UK price will rise by 170% in September, prompting interest in cheaper alternatives like semaglutide for weight loss.

International Business Times UK

Eli Lilly Mounjaro UK Price Increase Set To Soar By Up To 170%—Private Patients Facing £330 Monthly Costs

Eli Lilly will raise UK private prices for Mounjaro by up to 170 percent from September 2025, with the highest dose set to cost £330 monthly while NHS prices stay unchanged.

Benzinga

Eli Lilly Strikes $1.3 Billion Deal With Superluminal To Develop AI-Driven Obesity Drugs

Eli Lilly and Co (NYSE:LLY) has entered into a $1.3 billion deal with Superluminal Medicines to develop small-molecule drugs through artificial intelligence (AI) to treat obesity and other cardiometabolic diseases.

1 … 9 10 11 12

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Covid-19

31,137 stories

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.